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A B S T R A C T
34-year old patient had history of muscular wasting, easy fatigability, pain in extremities and waddling gait since
age of four. During the time, neuromuscular disease was suspected, but not confirmed. Elevated bone alkaline phospha-
tase as well as other bone turnover markers (osteocalcin, procollagen, telopeptide) indicated further skeletal evaluation.
Symmetrical enhanced uptake on technetium methylene diphosphonate [99mTc]MPD bone scintigraphy at diaphyses of
longitudinal bones and scull matched cortical thickening of long bones and sclerosis of the scull seen at radiograms.
Those findings pointed to Camurati-Engelmann disease misdiagnosed for the long time. This rare genetic autosomal
dominant disorder was retrospectively diagnosed in asymptomatic father too on the basis of bone scans done long time
ago. Old family member scans confirmed heredity pattern of the disease.
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Introduction
In 1920 Cockayne described a case of unusual bone
thickening in 9-years old child1. Two years later, Camu-
rati published a report of a father and a son having iden-
tical changes in lower limbs. He named this disease
‘symmetrical hereditary osteitis’, and determined later
the identical condition in four generation of the same
family2. In 1929 Engelmann described similar condition
in 8-years old boy and named it »osteopathica hyper-
ostotica (sclerotisans) multiplex infantilis«3. This syn-
drome is called today Camurati-Engelmann disease, or
progressive diaphyseal dysplasia. It is an autosomal dom-
inant disease, a part of the group of craniotubular hyper-
ostoses. Clinically, there is a great variability of symptoms.
Most of the patients experience pain in the extremities,
waddling gait, easy fatigability and muscle weakness4.
Symptoms mostly occur at younger age, although not
necessarily. Some of the patients have systemic manifes-
tation like anaemia, leucopaenia and hepatosplenomega-
ly. Main pathology is cortical thickening – hyperostosis,
appearing on the diaphyses of the long bones. The chan-
ges are present in bilateral and symmetrical pattern;
long bones of lower extremities are affected first, than
long bones of upper extremities, finally metaphyses. The
scull base and pelvis have sclerotic changes. Radiolo-
gically it is recognized by the symmetrical enlargement
with sclerosis of the cortex of long bones. Bone scan
shows abnormal uptake of technetium methylene di-
phosphonate- [99mTc]MPD in mentioned locations. Scle-
rosis of the skull and pelvis is seen too5,6. High bone turn-
over markers point to enhanced osteoblastic activity. In
755
Received for publication September 17, 2010
most of the cases Camurati-Engelmann disease is caused
by a mutation of coding region TGFb-1 (transforming
growth factor beta 1) located on chromosome 9q137.
TGFb-1 is a stimulator of osteoblastic bone formation.
The result of osteoblast enhanced action is failure of
bone resorption creating bilateral symmetrical cortical
thickening of the diaphyses of the long bones8.
Case Report
34-year old patient from a northern Croatian island
was presented with history of muscular wasting, easy
fatigability, pain in extremities and waddling gait since
the age of four. His locomotory problems could be de-
scribed as severe ones, they progressed during the time.
The patient had valgus deformity of the knee, scapulae
alate and low subcutaneous fat (densitometry of the fat
tissue showed only 18% of body fat). During the past
years diagnostic procedures were directed to determine
nature of his neuromuscular symptoms, though no neu-
rological or muscular damage was confirmed (electro-
neurography, neurological examination, muscular biop-
sies were normal). Throughout the time repeatedly
measured alkaline phosphatase was elevated. This find-
ing was consistent with other markers of bone turnover
performed during patients visit. Alkaline phosphatase
was elevated again (208 U/L; normal values for the lab.
<147), as well as osteocalcin 106.4 mg/L (<30 yr. normal
for the lab. 24–70), crosslaps 1.86 mg/L (<50 yr. normal
for the lab. <0.584) and procollagen 275.4 mg/L (normal
for the lab. 16.27–73.87), pointing to the bone metabolic
disease9. [99mTc]MPD bone scan showed symmetrical
enhanced uptake along longitudinal bones, scull and pel-
vis (Figure 1). Bone radiograms illustrated cortical thick-
ening symmetrically at diaphyses of femora, tibiae, fibu-
lae, humera (Figure 2) as well as sclerosis of scull. Those
findings matched bone scintigraphy (Figures 3 and 4).
Bone densitometry of forearms (BMD 1.120 T score +
8.2 Z score + 8.3) matched bone scan too. On the basis of
these findings, we believed that the diagnosis is Camu-
rati-Engelmann disease.
In differential diagnosis of the case there are several
sclerosing bone dysplasias, disorders that occur due to
disturbances in the pathways involved in osteoblast or
osteoclast regulation, leading to abnormal accumulation
of the bone. Those disorders share some clinical and ra-
diographic findings of Camurati-Engelmann disease,
though with some marked distinction. Some of them are
craniodiaphyseal dysplasia (distinguished by progressive
and marked enlargement of the midline cranial bones
causing facial deformity), Kenny-Caffey syndrome type 2
(distinguished by dwarfism and craniofacial anomaly),
juvenile Paget disease (distinguished by frequent frac-
tures, coarse trabeculations and bowing of the long bo-
nes), diaphyseal dysplasia with anemia (distinguished by
endosteal bone formation with no evidence of subperio-
steal bone formation, severe anemia and frequent infec-
tions), hyperostosis corticalis generalisata – Worth type
(distinguished by endosteal thickening without widening
of the diaphyseal shaft and wide deep mandible) and
sclerosteosis with van Buchem disease (distinguished by
variable syndactyly)10,11.
The most difficult to distinguish from Camurati-En-
gelmann disease is Ribbing disease, sclerosing dysplasia
of unknown etiology. Both diseases involve the diaphyses
of long tubular bones with sparing of the epiphyses, but
Ribbing disease is either unilateral or, if bilateral, always
asymmetric12. Asymmetry of the bone involvement was
not found in our patient. Ribbing disease is an adult con-
dition with higher incidence in women, in contradiction
with this case of male patient13. Finally, Ribbing disease
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Fig. 1. Bone scintigraphy: anterior and posterior. Fig. 2. Radiogram of right and left humerus.
is nonhereditary condition and we were able to find in-
heritance pattern.
All reachable family members were examined (mo-
ther, both sisters, grandparents from the mothers’ side),
but no clinical symptoms of the disease were found. Bone
scans of all family members were normal. Although pa-
tient’s father was not willing to accept present family
evaluation, we were able to track his old bone scan done
years ago (Figure 5). The clue why those scans were per-
formed at that time is still unclear, though it seems that
family physician was on the brink of discovery of a rare
diagnosis. Those old scans confirmed today that the fa-
ther has got the same diagnosis as a son. According to pa-
tient‘s and all other family member statements, father
had no clinical symptoms. According to the family photos
his phenotype is unobtrusive. Until now dominant inher-
itance from the father to son had not been suspected be-
cause of asymptomatic father.
There are not many treatment options for such rare
disease. One of them is etidronate, a first generation of
bisphosphonate that inhibits osteoclast-mediated bone
resorption. Etidronate is analog of pyrophosphate; when
a carbon is substituted for the oxygen the molecule can
enter the bones and inhibit mineralization. In that way it
binds strongly to hydroxyapatite crystals in the bone ma-
trix, inhibits directly mature osteoclast and promotes
osteoclast apoptosis. When given cyclically, etidronate is
effective for increasing the bone mineral density of lum-
bar spine and preventing vertebral fractures in patients
with osteoporosis. High etidronate doses (given continu-
ously) cause osteomalacia. This undesired side effect in
patient treated for osteoporosis is welcome in the case of
Camurati Engelmann disease14. 800 mg/day of etidronate
resulted in the drop of osteocalcin (a specific markers of
bone formation) level from 106 to 85 mg/L15. Despite that
finding, after 2 years of therapy patient’s symptoms did
not improve16.
Glucocorticoids are drugs with common side effects
on bone metabolism. They reduce bone formation and in-
crease bone resorption. The decline in bone formation is
mediated by direct inhibition of osteoblast proliferation/
differentiation and by an increase in the apoptosis rates
of mature osteoblasts and osteocytes17. Glucocorticoids
stimulate osteoclast proliferation by suppressing synthe-
sis of osteoprotegerin, an inhibitor of osteoclast differen-
tiation. They also stimulate osteoclast differentiation
and bone resorption through RANKL (receptor activator
of nuclear factor kappa-B ligand – surface-bound mole-
cule that activates osteoclasts)18. Lower rate of bone for-
mation and higher rate of bone resorption are progres-
sive diaphyseal dysplasia. Steroids, the most common
treatment option for Camurati-Engelmann disease, im-
prove the quality of life, decrease the pain but do not al-
ter the course of the disease19. In this case, only 24 mg of
methylprednisolone resulted in clinical improvement.
After one month of corticosteroid therapy patient re-
ported significantly less pain and fatigue.
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Fig. 3. Scull radiograms.
Fig. 4. Scull scintigraphy.
Fig. 5. Father’s bone scintigraphy.
Discussion
There are almost 90 years since the first descriptions
of the two family members, just like in this case of father
and son, suffering from progressive diaphyseal dysplasia.
This rare genetic autosomal dominant disorder is still of-
ten misdiagnosed. Extreme phenotypic variability in cli-
nical presentation not only in different families, but also
among family members, unpredictable severity and dif-
ferent age of onset often deceives physicians. In this case
severe clinical manifestation, laboratory results X-rays
and bone scan led towards the diagnosis of Camurati-
-Engelmann disease. Bone scintigraphy of a patient sho-
wed increased accumulation in long bones pelvis and
scull, a consequence of high osteoblastic activity caused
by TGFb-1 stimulation, a finding typical for this disea-
se14. Finally, old bone scans of the father matching his
son’s scans confirmed heredity of the disease. An old, al-
most forgotten bone scan of the parent revealed the diag-
nosis and confirmed the inheritance pattern. Careful
clinical examination of the patient and the family com-
bined with bone scintigraphy seems to be necessary in
confirming or ruling out progressive diaphyseal dyspla-
sia, even without genetic testing20.
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CAMURATI-ENGELMANNOVA BOLESTI U OBITELJI S HRVATSKOG OTOKA:
STARA SNIMKA KOSTIJU POTVRDILA JE OBRAZAC NASLJE\IVANJA
S A @ E T A K
34-godi{nji bolesnik od svoje ~etvrte godine u povijesti bolesti navodi mi{i}nu slabost, u~estalo umaranje, bolove u
rukama i nogama ti gegaju}i hod. Niz godina obra|ivan je zbog sumnje na neuromuskularnu bolest koja nije potvr|ena.
Povi{ena ko{tana alkalna fosfataza, kao i ostali markeri ko{tane pregradnje (osteokalcin, telopeptid, prokolagen) indi-
cirali su obradu ko{tanog sustava. Scintigrafija kostiju sa [99mTc]MPD pokazala je simetri~no poja~ano nakupljanje u
dugim kostima i na bazi lubanje {to odgovaralo zadebljanju kortikalisa dugih kostiju i sklerozi baze lubanje prikazane
na radiolo{kim snimkama. Snimke su ukazale na Camurati-Engelmannovu bolest ~ija dijagnoza promakla dugo vreme-
na. Radi se o rijetkoj genetskoj autosomno dominantnoj bolesti koja se kasnije dijagnosticirala i kod bolesnikova oca.
Stare snimke ~lana obitelji potvrdile su nasljedni obrazac bolesti.
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